Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer
Pancreatic cancer is among the most lethal malignant neoplasms, and few patients with pancreatic cancer benefit from immunotherapy. We retrospectively analyzed advanced pancreatic cancer patients who received PD-1 inhibitor-based combination therapies during 2019–2021 in our institution. The clinica...
Shranjeno v:
| Principais autores: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Taylor & Francis Group
2023-01-01
|
| Serija: | Human Vaccines & Immunotherapeutics |
| Teme: | |
| Online dostop: | http://dx.doi.org/10.1080/21645515.2023.2178791 |
| Oznake: |
Brez oznak, prvi označite!
|